George Prendergast

Dr. Prendergast is an accomplished cancer researcher with experience in the pharmaceutical industry as well as in academia, recognized for his expertise in cancer biology, signal transduction, and molecular therapeutics.

Throughout his career, he has become known as an innovator who has the ability to translate basic research findings toward clinical application, most recently in developing a novel drug-like therapy to improve the immune response against cancer.

He currently is president and CEO of the Lankenau Institute for Medical Research and a professor in the Department of Pathology, Anatomy & Cell Biology, Jefferson Medical School, Thomas Jefferson University. He also is co-director of the Program in Cell Biology & Signaling, KCC, Thomas Jefferson University.

Dr. Prendergast has contributed articles to numerous publications in the field of cancer research and is an inventor or co-inventor on a number of published or pending patents.